Lantus Versus Levemir Treat-To-Target

Inclusion Criteria: * Type 2 diabetes for at least 1 year * Insulin naïve * Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day) * 7% ≤ HbA1c ≤ 10.5 % * Body mass index (BMI) \< 40 kg/m² * Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary Exclusion Criteria: * Type 1 diabetes * Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week) * Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors * Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry) * Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method) * Breast-feeding * History of hypersensitivity to the study drugs or to drugs with a similar chemical structure * Treatment with systemic corticosteroids in the 3 months prior to study entry * Treatment with any investigational product in the 2 months prior to study entry * Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol * Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult * Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry * Impaired renal function as shown by serum creatinine ≥ 1.5 mg/dL (≥ 133 μmol/L) in men and ≥ 1.4 mg/dL (124 μmol/L) in women at study entry * History of drug or alcohol abuse in the last year The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.